Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
TLR sensing of pathogens triggers monocyte activation to initiate the host innate immune response to infection. Monocytes can dynamically adapt to different TLR agonists inducing different patterns of inflammatory response, and the sequence of exposure to TLRs can dramatically modulate cell activation. Understanding the interactions between TLR signalling that lead to synergy, priming and tolerance to TLR agonists may help explain how prior infections and inflammatory conditioning can regulate the innate immune response to subsequent infections. Our goal was to investigate the role of MyD88-independent/dependent TLR priming on modulating the monocyte response to LPS exposure. We stimulated human blood monocytes with agonists for TLR4 (LPS), TLR3 (poly(I:C)) and TLR7/8 (R848) and subsequently challenged them to low doses of endotoxin. The different TLR agonists promoted distinct inflammatory signatures in monocytes. Upon subsequent LPS challenge, LPS- and R848-primed monocytes did not enhance the previous response, whereas poly(I:C)-primed monocytes exhibited a significant inflammatory response concomitant with a sharp reduction on cell viability. Our results show that TLR3-primed monocytes are prompted to cell death by apoptosis in the presence of low endotoxin levels, concurrent with the production of high levels of TNFα and IL6. Of note, blocking of TNFR I/II in those monocytes did reduce TNFα production but did not abrogate cell death. Instead, direct signalling through TLR4 was responsible of such effect. Collectively, our study provides new insights on the effects of cross-priming and synergism between TLR3 and TLR4, identifying the selective induction of apoptosis as a strategy for TLR-mediated host innate response.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism

  • Matalonga, Jonathan
  • Glaria, Estibaliz
  • Bresque, Mariana|||0000-0002-4570-3629
  • Escande, Carlos|||0000-0002-9611-0903
  • Carbó, José María|||0000-0001-8301-5360
  • Kiefer, Kerstin
  • Vicente, Ruben
  • León, Theresa E.
  • Beceiro, Susana
  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Serret, Joan
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Riera, Antoni|||0000-0001-7142-7675
  • Paytubi, Sonia
  • Antonio Juarez, Antonio
  • Sotillo, Fernando
  • Lindbom, Lennart
  • Caelles, Carme
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Sancho, Jaime
  • Castrillo, Antonio|||0000-0002-2057-2159
  • Chini, Eduardo N.
  • Valledor, Annabel F.|||0000-0003-4232-2633
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages.remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis

  • Kroesen, Vera Marie
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • García, Eric
  • Rosales, Yaiza
  • Díaz, Jorge
  • Martín-Céspedes, Montse
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vilaplana, Cristina|||0000-0002-2808-7270
An excessive, non-productive host-immune response is detrimental in active, chronic tuberculosis (TB) disease as it typically leads to tissue damage. Given their anti-inflammatory effect, non-steroidal anti-inflammatory drugs can potentially attenuate excessive inflammation in active TB disease. As such, we investigated the prophylactic and therapeutic effect of low-dose aspirin (LDA) (3 mg/kg/day), either alone or in combination with common anti-TB treatment or BCG vaccination, on disease outcome in an experimental murine model of active TB. Survival rate, bacillary load (BL) in lungs, and lung pathology were measured. The possible mechanism of action of LDA on the host's immune response was also evaluated by measuring levels of CD5L/AIM, selected cytokines/chemokines and other inflammatory markers in serum and lung tissue. LDA increased survival, had anti-inflammatory effects, reduced lung pathology, and decreased bacillary load in late-stage TB disease. Moreover, in combination with common anti-TB treatment, LDA enhanced survival and reduced lung pathology. Results from the immunological studies suggest the anti-inflammatory action of LDA at both a local and a systemic level. Our results showed a systemic decrease in neutrophilic recruitment, decreased levels of acute-phase reaction cytokines (IL-6, IL-1β, and TNF-α) at late stage and a delay in the decrease in T cell response (in terms of IFN-γ, IL-2, and IL-10 serum levels) that occurs during the course of Mycobacterium tuberculosis infection. An anti-inflammatory milieu was detected in the lung, with less neutrophil recruitment and lower levels of tissue factor. In conclusion, LDA may be beneficial as an adjunct to standard anti-TB treatment in the later stage of active TB by reducing excess, non-productive inflammation, while enhancing Th1-cell responses for elimination of the bacilli.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Contribution of Elevated Glucose and Oxidized LDL to Macrophage Inflammation, A Role for PRAS40/Akt-Dependent Shedding of Soluble CD14

  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Villalmanzo, Núria
  • Téllez, Érica|||0000-0003-1034-6307
  • Ramírez-Morros, Anna|||0000-0001-8263-1292
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
Atherosclerosis, a process in which macrophages play a key role, is accelerated in diabetes. Elevated concentrations of serum-oxidized low-density lipoproteins (oxLDL) represent a common feature of both conditions. The main goal of this study was to determine the contribution of oxLDL to the inflammatory response of macrophages exposed to diabetic-mimicking conditions. THP1 cells and peripheral blood monocytes purified from non-diabetic healthy donors were cultured under normal (5 mM) or high glucose (HG) (15 mM) with oxLDL. Then, foam cell formation, expression of CD80, HLADR, CD23, CD206, and CD163, as well as toll-like receptor 4 (TLR4) and co-receptors CD36 and CD14 (both at the cell surface and soluble (sCD14)), and inflammatory mediators' production were measured by flow cytometry, RT-qPCR, or ELISA. Additionally, serum sCD14 was determined in subjects with subclinical atherosclerosis with and without diabetes by ELISA. Our results showed that oxLDL-mediated intracellular lipid accumulation via CD36 increased under HG and that HG + oxLDL enhanced TNF, IL1B, and IL8, and decreased IL10. Moreover, TLR4 was upregulated in macrophages under HG and monocytes of subjects with diabetes and atherosclerosis. Interestingly, HG-oxLDL upregulated CD14 gene expression, although its total cellular protein abundance remained unaltered. sCD14 shedding via PRAS40/Akt-dependent mechanisms, with pro-inflammatory activity, was significantly increased in cultured macrophages and plasma from subjects with diabetes and subclinical atherosclerosis or hypercholesterolemia. Our data support an enhanced synergistic pro-inflammatory effect induced by HG and oxLDL in cultured human macrophages, possibly explained by increased sCD14 shedding.